What Matters Most to Alzheimer’s Patients and Caregivers?
By: Phyllis Ferrell
5.7 million. That’s how many Americans are living with Alzheimer’s disease. By 2050, that number is projected to almost triple. And it is not just those living with the disease that are impacted. There are currently more than 15 million caregivers in the U.S. providing an estimated 18.1 billion hours of unpaid care to loved ones.
Yes, the statistics are daunting. Finding treatments for this deadly disease has never been more urgent. However, we believe that continued innovation and an emphasis on collaboration will yield results – which is why Lilly remains deeply committed to finding real solutions for Alzheimer’s disease.
For too long, the needs of Alzheimer’s patients and caregivers have not been at the forefront of research discussions. This is why USAgainstAlzheimer’s is launching the first-of-its-kind Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE) Initiative. The initiative gives patients and caregivers a direct voice and avenue to accelerate Alzheimer’s research.
AD PACE’s A-LIST is the authoritative ‘patient voice’ group that will help inform and improve many aspects of the research process, including clinical trial design. The A-LIST already includes over 6,000 members eager to share their experiences and unique needs. On May 23 from 7-8 PM ET, you’ll have the opportunity to hear from some of these members at a special Facebook Live event. We hope you’ll tune in to hear how patients, caregivers, and industry researchers are leading the fight to end Alzheimer’s.
To succeed in finding meaningful treatments for Alzheimer’s disease, we must be innovative in the way we approach challenges and research. As a leader in the industry, we recognize and value the importance of the patient and caregiver perspective in finding solutions. Partnering with USAgainstAlzheimer’s on AD PACE is an important step in continuing to take on this challenge.